CellaVision, which develops and sells digital morphology products for the routine analysis of blood and other body fluids, has been given official approval for marketing the company's analyzers CellaVision® DM in Japan. The products will be marketed and sold by CellaVison's newly established subsidiary in Japan, CellaVision Japan K.K.
"The establishment of our Japanese subsidiary is advancing according to plan and it is satisfying to now be active on the Japanese market. We hope to be completely operative before the end of the year", says CellaVision's CEO Yvonne Mårtensson. "It is important for us to meet potential clients on site in order to demonstrate how also Japanese laboratories can benefit from CellaVision's digital morphology technology. We see considerable potential in the Japanese market." Japan is the world's second largest market with around 9000 hospitals and 900 commercial laboratories, and has large potential for medical technology products in general. CellaVision will primarily focus on the approximately 1000 larger hospital and commercial laboratories benefitting the most from automating their processes.
The Japanese subsidiary will officially be opened during a ceremony at the Swedish Embassy in Tokyo on the 11th of September, 2008. On October 9-11, CellaVision's products will be presented at Japan's largest convention for clinical laboratory products, JSCLA, in Yokohama. The convention is expected to attract around 7000 key persons in clinical chemistry. The product registration has been issued by the Japanese authority Pharmaceuticals and Medical Device Agency (PMDA).
For more information, please contact: Yvonne Mårtensson, CEO, CellaVision AB Mobile: +46 708-33 77 82. E-mail: email@example.com
About CellaVision CellaVision AB develops, markets, and sells the market leading image analysis based systems for routine analysis of blood and other body fluids. The company has a core competence in development of software and hardware for automatic image analysis of cells and cell changes for applications in health and medical care. The company develops and markets systems for automatic differentials of white blood cells and red morphology, and software for education and quality assurance of differentials. The company's associates have expertise in advanced imaging analysis, artificial intelligence, and automated microscopy. The company headquarters are in Lund, Sweden. The company also has subsidiaries in Florida, USA, Toronto, Canada and Yokohama, Japan. For more information, visit www.cellavision.com.
CellaVision's share is listed on First North at the OMX Stockholm Stock Exchange. The company's Certified Advisor is Remium AB.